medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/ms2024-226medsovet-8352Research ArticleЗАБОЛЕВАНИЯ КИШЕЧНИКАBOWEL DISEASESВлияние устекинумаба на внекишечные проявления у пациентов с болезнью Крона или язвенным колитомEffect of ustekinumab on extraintestinal manifestations in patients with Crohn’s disease or ulcerative colitishttps://orcid.org/0000-0001-7069-2725АбдулганиеваД. И.AbdulganievaD. I.

Абдулганиева Диана Ильдаровна, д.м.н., профессор, заведующая кафедрой госпитальной терапии,

420012, Казань, ул. Бутлерова, д. 49

Diana I. Abdulganieva, Dr. Sci. (Med.), Professor, Head of the Department of Hospital Therapy,

49, Butlerova St., Kazan, 420012

diana.abdulganieva@kazangmu.ruhttps://orcid.org/0000-0003-2102-0142МухаметоваД. Д.MukhametovaD. D.

Мухаметова Диляра Дамировна, к.м.н., ассистент кафедры госпитальной терапии, 

420012, Казань, ул. Бутлерова, д. 49

Dilyara D. Mukhametova, Cand. Sci. (Med.), Assistant of the Department of Hospital Therapy,

49, Butlerova St., Kazan, 420012

muhdilyara@gmail.comКазанский государственный медицинский университетРоссияKazan State Medical UniversityRussian Federation20241006202408135142Copyright © Абдулганиева Д.И., Мухаметова Д.Д., 20242024Абдулганиева Д.И., Мухаметова Д.Д.Abdulganieva D.I., Mukhametova D.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/8352

В настоящем обзоре представлены основные внекишечные проявления (ВКП) у пациентов с воспалительными заболеваниями кишечника (ВЗК), в частности при язвенном колите (ЯК) и болезни Крона (БК), описано современное представление о механизмах развития, классификации, характеристике и частоте основных ВКП (суставные, кожные, офтальмологические проявления, поражение слизистых). Также подробно освещены вопросы механизма действия, показания для назначения устекинумаба, выделено место устекинумаба в терапии ВЗК, проведена оценка эффективности данного препарата в отношение терапии ВКП – обобщены результаты ретроспективного анализа данных программы клинических исследований UNITI-1, UNITI-2, IM-UNITI, проспективных когортных исследований, ретроспективных когортных исследований и регистрового исследования о влиянии устекинумаба на течение различных ВКП и исходы иммуноопосредованных заболеваний (ИОЗ) у пациентов с БК и ЯК. Устекинумаб представляет собой полностью моноклональный человеческий иммуноглобулин G1k, связывающийся с общей субъединицей p40 интерлейкина (ИЛ)-12 и ИЛ-23, которые принимают активное участие не только в развитии кишечной симптоматики, но и являются пусковыми в развитии различных ВКП. Обзор литературы показал, что устекинумаб может быть эффективен для лечения ВКП у пациентов с ЯК и БК, особенно в отношении дерматологических и ревматологических проявлений, псориаза и псориатического артрита. Поиск литературных источников был проведен с использование баз данных MEDLINE®, EMBASE®, BIOSIS Previews®, DERWENT® и (или) другим ресурсам, включая внутренние/внешние базы данных, 15 апреля 2024 г.

This review presents the main extraintestinal manifestations (EIMs) in patients with inflammatory bowel diseases (IBD), in particular ulcerative colitis (UC) and Crohn’s disease (CD), describes the modern potential mechanisms, classification, characteristics and frequency of the main EIMs (rheumatological, skin, ophthalmological and orofacial manifestations). The issues of the mechanism of action, indications for prescribing ustekinumab are also covered in detail, the place of ustekinumab in the treatment of IBD is highlighted, the effectiveness of this drug in relation to the treatment of IBD is assessed – summarizes the results of a retrospective analysis of data from the UNITI-1, UNITI-2, IM-UNITI clinical trial program, prospective cohort studies, retrospective cohort studies and a registry study on the effect of ustekinumab on the course of various EIMs and the outcomes of immune-mediated diseases (IMDs) in patients with CD and UC. Ustekinumab is a fully monoclonal human immunoglobulin G1k that binds to the common p40 subunit of interleukin (IL)-12 and IL-23, which are actively involved not only in the development of intestinal symptoms, but are also triggers in the development of various EIMs. A review of the literature showed that ustekinumab may be effective for the treatment of EIMs in patients with UC and CD, especially in relation to dermatological and rheumatological manifestations, and is effective against psoriasis and psoriatic arthritis. A literature search of MEDLINE®, EMBASE®, BIOSIS Previews® and DERWENT® and/or other resources, including internal/external databases was conducted on April 15, 2024.

воспалительные заболевания кишечникамеханизм развитиякожные проявлениясуставные проявленияпсориазinflammatory bowel diseasespathogenesisdermatological manifestationsrheumatological manifestationspsoriasisReferencesМаев ИВ, Бакулин ИГ, Скалинская МИ, Сказываева ЕВ. Воспалительные заболевания кишечника: трансформация представлений. Терапевтический архив. 2023;95(12):1064–1074. https://doi.org/10.26442/00403660.2023.12.202507.Maev IV, Bakulin IG, Skalinskaya MI, Skazyvaeva EV. Inflammatory bowel diseases: Transformation of representations. A review. Terapevticheskii Arkhiv. 2023;95(12):1064–1074. (In Russ.) https://doi.org/10.26442/00403660. 2023.12.202507.Шелыгин ЮА, Ивашкин ВТ, Белоусова ЕА, Решетов ИВ, Маев ИВ, Ачкасов СИ и др. Язвенный колит (К51), взрослые. Колопроктология. 2023;22(1):10–44. https://doi.org/10.33878/2073-7556-2023-22-1-10-44.Shelygin YA, Ivashkin VT, Belousova EA, Reshetov IV, Maev IV, Achkasov SI et al. Ulcerative colitis (К51), adults. Koloproktologia. 2023;22(1):10–44. (In Russ.) https://doi.org/10.33878/2073-7556-2023-22-1-10-44.Шелыгин ЮА, Ивашкин ВТ, Ачкасов СИ, Решетов ИВ, Маев ИВ, Белоусова ЕА и др. Клинические рекомендации. Болезнь Крона (К50), взрослые. Колопроктология. 2023;22(3):10–49. https://doi.org/10.33878/2073-7556-2023-22-3-10-49.Shelygin YA, Ivashkin VT, Achkasov SI, Reshetov IV, Maev IV, Belousova EA et al. Clinical guidelines. Crohn’s disease (К50), adults. Koloproktologia. 2023;22(3):10–49. (In Russ.) https://doi.org/10.33878/2073-7556-2023-22-3-10-49.Белоусова ЕА, Шелыгин ЮА, Ачкасов СИ, Хатьков ИЕ, Бакулин ИГ, Скалинская МИ и др. Клинико-демографические характеристики и лечебные подходы у пациентов с воспалительными заболеваниями кишечника (болезнь Крона, язвенный колит) в РФ. Первые результаты анализа национального регистра. Колопроктология. 2023;1(83):65–82. https://doi.org/10.33878/2073-7556-2023-22-1-65-82.Belousova EA, Shelygin YuA, Achkasov SI, Khatkov IE, Bakulin IG, Skalinskaya MI et al. Clinical and demographic features and treatment approaches for inflammatory bowel diseases (Crohn’s disease, ulcerative colitis) in the Russia. The primery results of the analysis of the National Register. Koloproktologia. 2023;22(1):65–82. (In Russ.) https://doi.org/10.33878/2073-7556-2023-22-1-65-82.Белоусова ЕА, Абдулганиева ДИ, Алексеева ОП, Алексеенко СА, Барановский АЮ, Валуйских ЕЮ и др. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018;46(5):445–463. https://doi.org/10.18786/2072-0505-2018-46-5-445-463.Belousova EA, Abdulganieva DI, Alexeeva OP, Alexeenko SA, Baranovsky AYu, Valuyskikh EYu et al. Social and demographic characteristics, features of disease course and treatment options of inflammatory bower disease in Russia: Results of two multicenter studies. Almanac of Clinical Medicine. 2018;46(5):445–463 (In Russ.) https://doi.org/10.18786/2072-0505-2018- 46-5-445-463.Gordon H, Burisch J, Ellul P, Karmiris K, Katsanos K, Allocca M et al. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2024;18(1):1–37. https://doi.org/10.1093/ecco-jcc/jjad108.Gordon H, Burisch J, Ellul P, Karmiris K, Katsanos K, Allocca M et al. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2024;18(1):1–37. https://doi.org/10.1093/ecco-jcc/jjad108.Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology. 2021;161(4):1118–1132. https://doi.org/10.1053/j.gastro.2021.07.042.Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology. 2021;161(4):1118–1132. https://doi.org/10.1053/j.gastro.2021.07.042.Ferreira SDC, Oliveira BBMD, Morsoletto AM, Martinelli CADL, Troncon LEDA. Extraintestinal manifestations of inflammatory bowel disease: Clinical aspects and pathogenesis. J Gastroenterol Dig Dis. 2018;3(1):4–11. Available at: https://www.alliedacademies.org/articles/extraintestinalmanifestations-of-inflammatory-bowel-disease-clinical-aspects-andpathogenesis-9942.html.Ferreira SDC, Oliveira BBMD, Morsoletto AM, Martinelli CADL, Troncon LEDA. Extraintestinal manifestations of inflammatory bowel disease: Clinical aspects and pathogenesis. J Gastroenterol Dig Dis. 2018;3(1):4–11. Available at: https://www.alliedacademies.org/articles/extraintestinalmanifestations-of-inflammatory-bowel-disease-clinical-aspects-andpathogenesis-9942.html.Adam H, Alqassas M, Saadah OI, Mosli M. Extraintestinal Manifestations of Inflammatory Bowel Disease in Middle Eastern Patients. J Epidemiol Glob Health. 2020;10(4):298–303. https://doi.org/10.2991/jegh.k.200330.001.Adam H, Alqassas M, Saadah OI, Mosli M. Extraintestinal Manifestations of Inflammatory Bowel Disease in Middle Eastern Patients. J Epidemiol Glob Health. 2020;10(4):298–303. https://doi.org/10.2991/jegh.k.200330.001.Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, Navarini AA et al. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort/ Inflamm Bowel Dis. 2015;21(8):1794–1800. https://doi.org/10.1097/MIB.0000000000000429.Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, Navarini AA et al. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort/ Inflamm Bowel Dis. 2015;21(8):1794–1800. https://doi.org/10.1097/MIB.0000000000000429.Hedin CRH, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L et al. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. J Crohns Colitis. 2019;13(5):541–554. https://doi.org/10.1093/ecco-jcc/jjy191.Hedin CRH, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L et al. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. J Crohns Colitis. 2019;13(5):541–554. https://doi.org/10.1093/ecco-jcc/jjy191.Kim JM, Cheon JH. Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases. Intest Res. 2020;18(3):249-264. https://doi.org/10.5217/ir.2019.00128.Kim JM, Cheon JH. Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases. Intest Res. 2020;18(3):249-264. https://doi.org/10.5217/ir.2019.00128.Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8 – entheseal resident T cells. Nat Med. 2012;18(7):1069–1076. https://doi.org/10.1038/nm.2817.Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8 – entheseal resident T cells. Nat Med. 2012;18(7):1069–1076. https://doi.org/10.1038/nm.2817.Walldorf J, Twarz M, Schober C, Michl P, Hammer T. High frequency of secondary, but not primary ocular manifestations of inflammatory bowel disease in patients treated at a tertiary care center. Eur J Gastroenterol Hepatol. 2018;30(12):1502–1506. https://doi.org/10.1097/MEG.0000000000001248.Walldorf J, Twarz M, Schober C, Michl P, Hammer T. High frequency of secondary, but not primary ocular manifestations of inflammatory bowel disease in patients treated at a tertiary care center. Eur J Gastroenterol Hepatol. 2018;30(12):1502–1506. https://doi.org/10.1097/MEG.0000000000001248.Narula N, Aruljothy A, Wong ECL, Homenauth R, Alshahrani AA, Marshall JK, Reinisch W. The impact of ustekinumab on extraintestinal manifestations of Crohn’s disease: A post hoc analysis of the UNITI studies. United European Gastroenterol J. 2021;9(5):581–589. https://doi.org/10.1002/ueg2.12094.Narula N, Aruljothy A, Wong ECL, Homenauth R, Alshahrani AA, Marshall JK, Reinisch W. The impact of ustekinumab on extraintestinal manifestations of Crohn’s disease: A post hoc analysis of the UNITI studies. United European Gastroenterol J. 2021;9(5):581–589. https://doi.org/10.1002/ueg2.12094.Aboubakr A, Battat R, Galati JS, Ahmed W, Scherl EJ, Longman RS, Lukin DJ. Su460 Effectiveness of ustekinumab for management of extraintestinal manifestations of Crohn’s disease. Gastroenterology. 2021;160(6):701. https://doi.org/10.1016/S0016-5085(21)02382-9.Aboubakr A, Battat R, Galati JS, Ahmed W, Scherl EJ, Longman RS, Lukin DJ. Su460 Effectiveness of ustekinumab for management of extraintestinal manifestations of Crohn’s disease. Gastroenterology. 2021;160(6):701. https://doi.org/10.1016/S0016-5085(21)02382-9.de Risi-Pugliese T, Seksik P, Bouaziz JD, Chasset F, Moguelet P, Gornet J-M et al. Ustekinumab treatment for neutrophilic dermatoses associated with Crohn’s disease: a multicenter-retrospective study. J Am Acad Dermatol. 2018;80(3):781–784. https://doi.org/10.1016/j.jaad.2018.06.065.de Risi-Pugliese T, Seksik P, Bouaziz JD, Chasset F, Moguelet P, Gornet J-M et al. Ustekinumab treatment for neutrophilic dermatoses associated with Crohn’s disease: a multicenter-retrospective study. J Am Acad Dermatol. 2018;80(3):781–784. https://doi.org/10.1016/j.jaad.2018.06.065.Tursi A, Mocci G, Maconi G. Effect of ustekinumab on extraintestinal diseases in refractory Crohn’s disease. J Crohns Colitis. 2021;15(8):1399–1400. https://doi.org/10.1093/ecco-jcc/jjab028.Tursi A, Mocci G, Maconi G. Effect of ustekinumab on extraintestinal diseases in refractory Crohn’s disease. J Crohns Colitis. 2021;15(8):1399–1400. https://doi.org/10.1093/ecco-jcc/jjab028.Liefferinckx C, Verstockt B, Gils A, Noman M, Van Kemseke C, Macken E et al. Long-term clinical effectiveness of ustekinumab in patients with Crohn’s disease who failed biologic therapies: a national cohort study. J Crohn’s Colitis. 2019;13(11):1401–1409. https://doi.org/10.1093/ecco-jcc/jjz080.Liefferinckx C, Verstockt B, Gils A, Noman M, Van Kemseke C, Macken E et al. Long-term clinical effectiveness of ustekinumab in patients with Crohn’s disease who failed biologic therapies: a national cohort study. J Crohn’s Colitis. 2019;13(11):1401–1409. https://doi.org/10.1093/ecco-jcc/jjz080.Macaluso FS, Fries W, Viola A, Costantino G, Muscianisi M, Cappello M et al. Effectiveness of ustekinumab on Crohn’s disease associated spondyloarthropathy: real-world data from the Sicilian network for inflammatory bowel diseases (SN-IBD). Expert Opin Biol Th. 2020;20(11):1381–1384. https://doi.org/10.1080/14712598.2020.1830057.Macaluso FS, Fries W, Viola A, Costantino G, Muscianisi M, Cappello M et al. Effectiveness of ustekinumab on Crohn’s disease associated spondyloarthropathy: real-world data from the Sicilian network for inflammatory bowel diseases (SN-IBD). Expert Opin Biol Th. 2020;20(11):1381–1384. https://doi.org/10.1080/14712598.2020.1830057.Lai D, Funez-dePagnier G, Duenas-Bianchi L, Battat R, Ahmed W, Schwartzman M et al. 615 IBD-associated spondyloarthritis defines a more severe phenotype refractory to ustekinumab. Gastroenterology. 2021;160(6):122–123. https://doi.org/10.1016/S0016-5085(21)01047-7.Lai D, Funez-dePagnier G, Duenas-Bianchi L, Battat R, Ahmed W, Schwartzman M et al. 615 IBD-associated spondyloarthritis defines a more severe phenotype refractory to ustekinumab. Gastroenterology. 2021;160(6):122–123. https://doi.org/10.1016/S0016-5085(21)01047-7.Singh A, Khan F, Lopez R, Shen Bo. Ustekinumab for moderate to severe Crohn’s disease and its extraintestinal manifestations. Amer J Gastroenterol. 2017;112(1):1482. https://doi.org/10.14309/00000434-201710001-02733.Singh A, Khan F, Lopez R, Shen Bo. Ustekinumab for moderate to severe Crohn’s disease and its extraintestinal manifestations. Amer J Gastroenterol. 2017;112(1):1482. https://doi.org/10.14309/00000434-201710001-02733.Vizuete J, Randall C, Martinez N. Can ustekinumab relieve the symptoms of IBD-associated arthropathy? Amer J Gastroenterol. 2019;(1):482–483. https://doi.org/10.14309/01.ajg.0000592876.05700.5e.Vizuete J, Randall C, Martinez N. Can ustekinumab relieve the symptoms of IBD-associated arthropathy? Amer J Gastroenterol. 2019;(1):482–483. https://doi.org/10.14309/01.ajg.0000592876.05700.5e.Galan C, Truyens М, Peeters H, Gismero FM, Elorza A, Torres P et al. Safety of vedolizumab and ustekinumab in elderly IBD patients: a real-life multicentric cohort study. United European Gastroenterology J. 2021;9(1):554–555.Galan C, Truyens М, Peeters H, Gismero FM, Elorza A, Torres P et al. Safety of vedolizumab and ustekinumab in elderly IBD patients: a real-life multicentric cohort study. United European Gastroenterology J. 2021;9(1):554–555.Straatmijer T, Biemans VBC, Hoentjen F, de Boer NKH, Bodelier AGL, Dijkstra G et al. Ustekinumab for Crohn’s disease: two-year results of the Initiative on Crohn and Colitis (ICC) registry, a nationwide prospective observational cohort study. J Crohns Colitis. 2021;15(11):1920–1930. https://doi.org/10.1093/ecco-jcc/jjab081.Straatmijer T, Biemans VBC, Hoentjen F, de Boer NKH, Bodelier AGL, Dijkstra G et al. Ustekinumab for Crohn’s disease: two-year results of the Initiative on Crohn and Colitis (ICC) registry, a nationwide prospective observational cohort study. J Crohns Colitis. 2021;15(11):1920–1930. https://doi.org/10.1093/ecco-jcc/jjab081.Bennett A, Carlini LE, Duley C, Garrett A, Annis K, Wagnon J et al. A single center experience with long-term ustekinumab use and reinduction in patients with refractory Crohn disease. Crohn’s Colitis 360. 2020;2(1):otaa013. https://doi.org/10.1093/crocol/otaa013.Bennett A, Carlini LE, Duley C, Garrett A, Annis K, Wagnon J et al. A single center experience with long-term ustekinumab use and reinduction in patients with refractory Crohn disease. Crohn’s Colitis 360. 2020;2(1):otaa013. https://doi.org/10.1093/crocol/otaa013.Pugliese D, Daperno M, Fiorino G, Savarino E, Mosso E, Biancone L et al. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. Digest Liver Dis. 2019;51(7):972–977. https://doi.org/10.1016/j.dld.2019.03.007.Pugliese D, Daperno M, Fiorino G, Savarino E, Mosso E, Biancone L et al. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. Digest Liver Dis. 2019;51(7):972–977. https://doi.org/10.1016/j.dld.2019.03.007.Chaparro M, Hermida S, Acosta D, Fernández-Clotet A, Barreiro-de Acosta M, Martínez AH et al. Impact of ustekinumab on extraintestinal manifestations and immunomediated diseases in a cohort of patients with ulcerative colitis in real life: the Ulises study. J Crohns Colitis. 2018;(1):208–210.Chaparro M, Hermida S, Acosta D, Fernández-Clotet A, Barreiro-de Acosta M, Martínez AH et al. Impact of ustekinumab on extraintestinal manifestations and immunomediated diseases in a cohort of patients with ulcerative colitis in real life: the Ulises study. J Crohns Colitis. 2018;(1):208–210.Guillo L, D’Amico F, Danese S, Peyrin-Biroulet L. Ustekinumab for Extraintestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review. J Crohns Colitis. 2021;15(7):1236–1243. https://doi.org/10.1093/ecco-jcc/jjaa260.Guillo L, D’Amico F, Danese S, Peyrin-Biroulet L. Ustekinumab for Extraintestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review. J Crohns Colitis. 2021;15(7):1236–1243. https://doi.org/10.1093/ecco-jcc/jjaa260.

The authors declare that there are no conflicts of interest present.